Moleculin Biotech Stock Today
| MBRX Stock | USD 4.35 0.25 5.43% |
Performance0 of 100
| Odds Of DistressLess than 17
|
Moleculin Biotech is trading at 4.35 as of the 24th of April 2024; that is -5.43 percent decrease since the beginning of the trading day. The stock's open price was 4.6. Moleculin Biotech has less than a 17 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Moleculin Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of March 2024 and ending today, the 24th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of June 2016 | Category Healthcare | Classification Health Care |
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. The company has 2.23 M outstanding shares of which 44.95 K shares are now shorted by private and institutional investors with about 0.66 trading days to cover. More on Moleculin Biotech
Moving against Moleculin Stock
| 0.86 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.85 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.74 | XFOR | X4 Pharmaceuticals Earnings Call Next Week | PairCorr |
| 0.58 | ELYM | Eliem Therapeutics | PairCorr |
| 0.43 | NRSNW | NeuroSense Therapeutics | PairCorr |
Moleculin Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Moleculin Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Moleculin Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Moleculin Biotech report their recommendations after researching Moleculin Biotech's financial statements, talking to executives and customers, or listening in on Moleculin Biotech's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Moleculin Biotech. The Moleculin consensus assessment is calculated by taking the average forecast from all of the analysts covering Moleculin Biotech. | |||||
Moleculin Biotech's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Moleculin Biotech's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Moleculin Biotech's financial leverage. It provides some insight into what part of Moleculin Biotech's total assets is financed by creditors.
| |||||
Moleculin Biotech (MBRX) is traded on NASDAQ Exchange in USA. It is located in 5300 Memorial Drive, Houston, TX, United States, 77007 and employs 18 people. Moleculin Biotech is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.3 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Moleculin Biotech's market, we take the total number of its shares issued and multiply it by Moleculin Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Moleculin Biotech conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.23 M outstanding shares of which 44.95 K shares are now shorted by private and institutional investors with about 0.66 trading days to cover.
Moleculin Biotech currently holds about 58 M in cash with (24.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.03.
Check Moleculin Biotech Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Moleculin Biotech is currently $10.3 Million. Moleculin Biotech secures 4.64 % of its outstanding shares held by insiders and 15.51 % owned by institutional investors. Be advised that no matter how volatile the entity is, if the real value of the firm is more than the value suggested by the market, you should consider buying it.
Check Moleculin Ownership Details
Moleculin Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Moleculin Biotech jumping above the current price in 90 days from now is under 95%. The Moleculin Biotech probability density function shows the probability of Moleculin Biotech stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.2757. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Moleculin Biotech will likely underperform. Additionally, moleculin Biotech has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Moleculin Biotech to move above the current price in 90 days from now is under 95 (This Moleculin Biotech probability density function shows the probability of Moleculin Stock to fall within a particular range of prices over 90 days) .
Moleculin Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Moleculin Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Moleculin Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moleculin Biotech's value.| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2023-12-31 | 7.2 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 6.3 K | |
| Sandy Spring Bank | 2023-12-31 | 1.3 K | |
| Advisor Group Holdings, Inc. | 2023-12-31 | 968 | |
| Cva Family Office, Llc | 2023-12-31 | 500 | |
| North Star Investment Management Corp | 2023-12-31 | 250 | |
| Wells Fargo & Co | 2023-12-31 | 229 | |
| Nbc Securities Inc | 2023-09-30 | 200 | |
| Bank Of America Corp | 2023-12-31 | 138 | |
| Armistice Capital, Llc | 2023-12-31 | 3.2 M | |
| Vanguard Group Inc | 2023-12-31 | 1.1 M |
Moleculin Biotech Historical Income Statement
Moleculin Biotech Income Statement is one of the three primary financial statements used for reporting Moleculin's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Moleculin Biotech revenue and expense. Moleculin Biotech Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Moleculin Biotech's Interest Expense is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 131.9 K in 2024, whereas Interest Income is likely to drop slightly above 965.1 K in 2024. View More FundamentalsMoleculin Stock Against Markets
Picking the right benchmark for Moleculin Biotech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Moleculin Biotech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Moleculin Biotech is critical whether you are bullish or bearish towards Moleculin Biotech at a given time. Please also check how Moleculin Biotech's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Moleculin Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Moleculin Biotech Corporate Management
Elected by the shareholders, the Moleculin Biotech's board of directors comprises two types of representatives: Moleculin Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moleculin. The board's role is to monitor Moleculin Biotech's management team and ensure that shareholders' interests are well served. Moleculin Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moleculin Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Louis Ploth | Independent Advisor | Profile | |
| Walter Klemp | Chairman, Founder | Profile | |
| ScD MD | Senior Officer | Profile | |
| Jacqueline Northcut | Consultant | Profile | |
| Donald Picker | Chief Officer | Profile | |
| Waldemar Priebe | Founding CoFounder | Profile |
How to buy Moleculin Stock?
Before investing in Moleculin Biotech, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Moleculin Biotech. To buy Moleculin Biotech stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Moleculin Biotech. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Moleculin Biotech stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Moleculin Biotech stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Moleculin Biotech stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Moleculin Biotech, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.
Already Invested in Moleculin Biotech?
The danger of trading Moleculin Biotech is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Moleculin Biotech is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Moleculin Biotech. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Moleculin Biotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Moleculin Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moleculin Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moleculin Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moleculin Biotech Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Moleculin Stock analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.15) | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.